Gepotidacin is a novel, first-in-class antibiotic recently approved by the FDA for treating uncomplicated urinary tract infections (uUTIs). As a new...
Gepotidacin is a novel oral antibiotic, a first-in-class triazaacenaphthylene, recently approved by the FDA for treating uncomplicated urinary tract infections (uUTIs) in adults and adolescents.
Gepotidacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes involved in bacterial DNA replication and repair. This distinct mechanism helps it overcome resistance to other antibiotic classes.
Currently, Gepotidacin is approved by the FDA for the treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible microorganisms in females 12 years and older.
Its significance stems from being a new class of antibiotic, offering a vital new treatment option for uUTIs amidst increasing global antimicrobial resistance, providing an alternative where older antibiotics may be less effective.